[last updated : 2025/4/30]
The original article by Dr. Noboru Yamamoto et.al. from our departmenthas been published in “Journal of Clinical Oncology”.
The original article by Dr. Noboru Yamamoto et.al. from our departmenthas been published in “Journal of Clinical Oncology”.
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study